American investment group Carlyle will buy 20 percent in India’s Piramal Group company Piramal Pharma. The Carlile Group will pay $ 49 million, or Rs 3700 crore, for this. Piramal Enterprises gave this information on Saturday. In a communication sent to the stock markets, the Ajay Piramal-led company said that CA Clover Intermediate 2 Investments, a unit linked to CAP V Mauritius Ltd, invested equity capital for a 20 per cent stake in Piramal Pharma Ltd. Have agreed to do.
It is an investment fund, managed and managed by a unit of the Carlile Group Inc. About $ 49 million will be invested for a 20 percent stake in Piramal Pharma. However, the final amount of equity investment will depend on net credit and exchange rate. Piramal Pharma comprises Piramal Pharma Solution, Manufacturing Business, Piramal Critical Care, Hospital Complex and Generic Business.
This is the second pharma investment in India for American PE company Carlyle. Earlier, he had bought a stake in Sequent Scientific. . The company has also previously invested in Global Contract Research Development and Manufacturing Organization AMR. Carlyle’s Asia MD Neeraj Bhardwaj said that we are seeing attractive opportunities in the global pharma industry trend, which includes both organic and in-organic growth. We continue to deal in the healthcare sector, taking advantage of the knowledge of our global network.